NCT04712721View on ClinicalTrials.gov

Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

June 18, 2024

Study Completion Date

July 1, 2024

Conditions
Glioblastoma MultiformeBrain NeoplasmsGastroesophageal AdenocarcinomaPancreatic Ductal Adenocarcinoma
Interventions
DRUG

68Ga-FF58

Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.

Trial Locations (2)

45147

Novartis Investigative Site, Essen

69373

Novartis Investigative Site, Lyon

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY